ReviewJournal of gastroenterology2010
Gastrointestinal follicular lymphoma: review of the literature.
Review in Journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 113 citations in OpenAlex.
- Emerging role of lisocabtagene maraleucel chimeric antigen receptor-T cell in nodal and gastrointestinal follicular lymphoma.World journal of gastroenterology · 2025Article
- Gastrointestinal Follicular Lymphoma of the Cecum Treated via Endoscopic Full-Thickness Resection.ACG case reports journal · 2024Article
- Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas.World journal of gastroenterology · 2023Review
- Multifocal Follicular Lymphoma Isolated to the Gastrointestinal Tract: A Rare Finding.ACG case reports journal · 2023Article
- Endoscopic and Histopathological Characteristics of Gastrointestinal Lymphoma: A Multicentric Study.Diagnostics (Basel, Switzerland) · 2023Article
- Recent advances in treatment of nodal and gastrointestinal follicular lymphoma.World journal of gastroenterology · 2023Article
- Ascites as First Atypical and Only Clinical Manifestation of De Novo Follicular Lymphoma.Medicina (Kaunas, Lithuania) · 2022Article
- Protein-losing Enteropathy Complicated with Primary Intestinal Follicular Lymphoma.Internal medicine (Tokyo, Japan) · 2022Article
- Article
- Atypical jejunal follicular lymphoma with severe stricture.Clinical journal of gastroenterology · 2022Article
- Colo-enteric fistula associated with diffuse large B cell lymphoma that resulted in gastrointestinal bleeding: A case report and literature review.International journal of surgery case reports · 2022Article
- Article
- Article
- Squamous Metaplasia of the Stomach Associated with Lymphoma Infiltration.Internal medicine (Tokyo, Japan) · 2021Article
- B Cell Lymphomas of the GI Tract.Current gastroenterology reports · 2021Review
- Hematologic malignancies of the gastrointestinal luminal tract.Abdominal radiology (New York) · 2020Review
- Primary non-ampullary duodenal follicular lymphoma presenting with obstructive jaundice.Clinical journal of gastroenterology · 2020Article
- Endoscopic characteristics of small intestinal malignant tumors observed by balloon-assisted enteroscopy.World journal of gastrointestinal endoscopy · 2019Article
- Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma.Cancer research and treatment · 2019Article
- Colorectal follicular lymphoma: A case report.Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal follicular lymphoma (GI-FL) is a relatively rare disease, accounting for only 1%-3.6% of gastrointestinal non-Hodgkin's lymphoma. Although the duodenum and terminal ileum are considered to be the most common sites of origin, the development of wireless capsule endoscopy and double-balloon enteroscopy has increased the detection of GI-FL in every part of the small intestine. Approximately 70% of patients with GI-FL are estimated to have multiple lesions throughout the entire gastrointestinal tract. FL is a low-grade lymphoma that usually develops very slowly. If the lymphoma causes no symptoms, immediate treatment may not be necessary. Standard therapy has not yet been established for GI-FL, but chemotherapy, radiotherapy, monoclonal antibody therapy, or a combination of these therapies, is sometimes performed based on the therapeutic regimens for nodal FL. Regimens including conventional chemotherapy with rituximab, which achieve high response rates in nodal FL, are commonly used for GI-FL. The long-term clinical outcome of GI-FL is unclear. The results of a few series on the long-term outcomes of patients with GI-FL treated with conventional therapy indicate a median relapse-free time ranging from 31 to 45 months. On the other hand, in patients with GI-FL who were followed without treatment, the median time to disease progression was 37.5 months. Thus, whether to initiate aggressive therapy or whether to continue watchful waiting in patients with GI-FL is a critically important decision. Ongoing research on biomarkers to guide individualized GI-FL therapy may provide invaluable information that will lead to the establishment of a standard therapeutic regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.